Bain leads $150M round to push blindness biotech's rare disease drug toward FDA

Paul Schloesser

Associate Editor

Alkeus Pharmaceuticals has raised $150 million via a Series B round in order to advance a precision medicine candidate to treat Stargardt disease, a currently …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bain leads $150M round to push blindness biotech's rare disease drug toward FDA

Paul Schloesser

Associate Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Bain leads $150M round to push blind­ness biotech's rare dis­ease drug to­ward FDA

Associate Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Bain leads $150M round to push blindness biotech's rare disease drug toward FDA